Pathophysiologic therapeutic targets in hypertension: A cardiological point of view

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 2, 2012, Pages 179-193

  Fragasso, Gabriele ^a   Maranta, Francesco ^a   Montanaro, Claudia ^a   Salerno, Anna ^a   Torlasco, Camilla ^a   Margonato, Alberto ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Arterial hypertension; Pathophysiology; Reninangiotensinaldosterone; Sympathetic; Therapy

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHLORTALIDONE; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; LABETALOL; LISINOPRIL; METOPROLOL; TACHYKININ;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD FLOW; BLOOD PRESSURE; BLOOD VOLUME; COUGHING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; FOLLOW UP; GLUCOSE HOMEOSTASIS; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART RATE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; INCIDENCE; INSULIN RESISTANCE; INTERSTITIAL FLUID; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; META ANALYSIS (TOPIC); MONOTHERAPY; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; QUALITY OF LIFE; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; REVIEW; RISK REDUCTION; STROKE; SYMPATHETIC TONE; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

ADRENERGIC BETA-AGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; HUMANS; HYPERTENSION;

EID: 84857403998     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.655724     Document Type: Review

References (164)

1. Tang WHW. Metabolic approach in heart failure. Rethinking how we translate from theory to clinical practice. J Am Coll Cardiol 2006;48:999-1000
2. Morganti A. Randomized clinical trials on surrogate end points: are they useful for evaluating cardiovascular and renal disease protection in hypertension? The case for yes. J Am Soc Nephrol 2006;17:S141-4
3. Mancia G, Dell'Oro R, Quarti-Trevano F, et al. Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease. J Hypertens Suppl 2006;24:S51-6
4. Laragh JH, Sealey JE. Renin angiotensin aldosterone system and the renal regulation of sodium, potassium, and blood pressure homeostasis. In: Windhager EE, editor. Handblock of Physiology, Section 8, Renal physiology. Oxford University Press; New York: 1991. p. 1409-541
5. Mendlowitz M, Gitlow SE, Wolf RL, Naftchi NE. Mechanisms in essential hypertension. Dis Chest 1964;45:360-4
6. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52
7. Bennett WM, McDonald WJ, Kuehnel E, et al. Do diuretics have antihypertensive properties independent of natriuresis? Clin Pharmacol Ther 1977;22:499-504
8. Freis ED. How diuretics lower blood pressure. Am Heart J 1983;106:185-7
9. Insel PA, Motulsky HJ. A hypothesis linking intracellular sodium, membrane receptors, and hypertension. Life Sci 1984;34:1009-13
10. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALLHAT Research Group. Am J Hypertens 1996;9:342-60
11. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial l (ALLHAT). JAMA 2000;283:1967-75
12. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
13. Einhorn PT, Davis BR, Massie BM, et al. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) heart failure validation study: diagnosis and prognosis. Am Heart J 2007;153:42-53
14. Messerli FH. Doxazosin and congestive heart failure. J Am Coll Cardiol 2001;38:1295-6
15. Weber MA. The ALLHAT report: a case of information and misinformation. J Clin Hypertens 2003;5:9-13
16. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92
17. Bohlen HG. Localization of vascular resistance changes during hypertension. Hypertension 1986;8:181-3
18. Park JB, Schiffrin EL. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 2001;19:921-30
19. Zhou MS, Schulman IH, Jaimes EA, Raij L. Thiazide diuretics, endothelial function, and vascular oxidative stress. J Hypertens 2008;26:494-500
20. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991;14:203-9
21. Ferrari P, Rosman J, Weidmann P. Antihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol 1991;67:26B-35B
22. Eriksson JW, Jansson PA, Carlberg B, et al. Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension 2008;52:1030-7
23. Gupta AK, Dahlof B, Dobson J, et al. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-scandinavian cardiac outcomes trial-blood pressure lowering arm and the relative influence of antihypertensive medication. Diabetes Care 2008;31:982-8
24. Zillich AJ, Garg J, Basu S, et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006;48:219-24
25. Shafi T, Appel LJ, Miller ER III, et al. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension 2008;52:1022-9
26. Reungjui S, Pratipanawatr T, Johnson RJ, Nakagawa T. Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia. Curr Opin Nephrol Hypertens 2008;17:470-6
27. Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program. J Hypertens 2000;18:1149-54
28. Grassi G, Seravalle G, Dell'Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003;21:1761-9
29. Burnier M, Brunner HR. Neurohormonal consequences of diuretics in different cardiovascular syndromes. Eur Heart J 1992;13:G28-33
30. Whelton P, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:1401-9
31. Gress TW, Nieto FJ, Shahar E, For the Atherosclerosis Risk in Communities Study. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000;342:905-12
32. Kostis JB, Wilson AC, Freudenberger RS, et al. SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005;95:29-35
33. Fonseca FA, Ihara SS, Izar MC, et al. Hydrochlorothiazide abolishes the anti-atherosclerotic effect of quinapril. Clin Exp Pharmacol Physiol 2003;30:779-85
34. Carter BL, Einhorn PT, Brands M, et al. Working Group from the National Heart, Lung, and Blood Institute. Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension 2008;52:30-6
35. Wassertheil-Smoller S, Oberman A, Blaufox MD, et al. The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life. Am J Hypertens 1992;5:37-44
36. Derby CA, Barbour MM, Hume AL, McKinlay JB. Drug therapy and prevalence of erectile dysfunction in the Massachusetts Male Aging Study cohort. Pharmacotherapy 2001;21:676-83
37. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-9
38. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53
39. Bradley HA, Wiysonge CS, Volmink JA, et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006;24:2131-41
40. Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007;1:CD002003
41. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008;52:1482-9
42. Fragasso G, Cera M, Margonato A. Different metabolic effects of selective and non-selective beta-blockers rather than mere heart rate reduction may be the mechanism by which beta-blockade prevents cardiovascular events. J Am Coll Cardiol 2009;53:2105
43. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25
44. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004;17:118-23
45. Ram CV. Beta-blockers in hypertension. Am J Cardiol 2010;106:1819-25
46. Weidmann P, Beretta-Piccoli C, Ziegler W, et al. Interrelations between blood pressure, blood volume, plasma renin and urinary catecholamines during beta-blockade in essential hypertension. Klin Wochenschr 1976;54:765-73
47. Vatner SF, Hintze TH. Mechanism of constriction of large coronary arteries by beta-adrenergic receptor blockade. Circ Res 1983;53:389-400
48. Taddei S, Virdis A, Ghiadoni L, et al. Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J Hypertens 2001;19:1379-86
49. Schiffrin LE, Deng LY. Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist. J Hypertens 1996;14:1247-55
50. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-7
51. Piatti PM, Monti LD, Galli L, et al. Relationship between endothelin-1 concentrations and metabolic alterations typical of the Insulin Resistance Syndrome. Metabolism 2000;49:748-52
52. Eliasson K, Lins LE, Rossner S. Serum lipoprotein changes during atenolol treatment of essential hypertension. Eur J Clin Pharmacol 1981;20:335-8
53. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003;107:2747-52
54. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292:2227-36
55. Rizos E, Bairaktari E, Kostoula A, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 2003;8:127-34
56. Kaiser T, Heise T, Nosek L, et al. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 2006;24:1397-403
57. Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006;24:591-6
58. Mason RP, Kalinowski L, Jacob RF, et al. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 2005;112:3795-801
59. Pasini AF, Garbin U, Stranieri C, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens 2008;21:1251-7
60. Van Bortel LM, Fici F, Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs 2008;8:35-44
61. Greenland P, Daviglus ML, Dyer AR, et al. Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago heart association detection project in industry. Am J Epidemiol 1999;149:853-62
62. Mensink GB, Hoffmeister H. The relationship between resting heart rate and all-cause, cardiovascular and cancer mortality. Eur Heart J 1997;18:1404-10
63. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008;372:817-21
64. Balansard P, Chabrillat Y, Paulin R, et al. Effect of atenolol, a new cardioselective beta-blocker, on plasma renin activity in treatment of hypertension. Acta Cardiol 1977;32:229-43
65. Fagard R, Amery A, Deplaen JF, et al. Plasma renin concentration and the hypotensive effect of bendrofluazide and of atenolol. Clin Sci Mol Med Suppl 1976;3:215s-7s
66. Ishizaki T, Oyama Y, Suganuma T, et al. A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, beta-blockade and steady-state pharmacokinetics. Br J Clin Pharmacol 1983;16:17-25
67. Pitkajarvi T, Ylitalo P, Metsa-Ketela T, Vapaatalo H. The effects of a beta1-blocking agent, atenolol, on blood pressure, plasma renin activity and prostaglandin F2alpha excretion in patients with essential hypertension. Acta Med Scand 1979;206:107-13
68. Man in't Veld AJ, Van den Meiracker AH, Schalekamp MA. Do beta-blockers really increase peripheral vascular resistance? Review of the literature and new observations under basal conditions. Am J Hypertens 1988;1:91-6
69. Beto JA, Bansal VK. Quality of life in treatment of hypertension. Am J Hypertens 1992;5:125-33
70. Kendall MJ. Pharmacology of third generation beta blockers: greater benefits, fewer risks. J Cardiovasc Pharmacol 1989;14:S4-8
71. Nathan S, Pepine CJ, Bakris GL. Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension 2005;46:637-42
72. Hamada T, Watanabe M, Kaneda T, et al. Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine. J Hypertens 1998;16:111-18
73. Bonadue D, Petretta M, Ianniciello A, et al. Comparison of verapamil versus felodipine on heart rate variability after acute myocardial infarction. Am J Cardiol 1997;79:564-9
74. Kailasam MT, Parmer RJ, Cervenka JH, et al. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension 1995;26:143-9
75. Vaage-Nilsen M, Rasmussen V. Effect of Verapamil on heart rate variability after an acute myocardial infarction. Cardiovasc Drugs Ther 1998;12:285-90
76. Staszewska-Woolley J. Modification by diltiazem, a calcium antagonist, of the pulmonary vagal and cardiac sympathetic chemoreflexes in the dog. Clin Exp Pharmacol Physiol 1987;14:455-64
77. Giudicelli JF, Berdeaux A, Edouard A, et al. Attenuation by diltiazem of arterial baroreflex sensitivity in man. Eur J Clin Pharmacol 1984;26:675-9
78. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739-45
79. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31
80. Furberg CD, Psaty BM. Should calcium antagonists be first line drugs in hypertension? Herz 1995;20:365-9
81. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35
82. Marwick C. FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards. JAMA 1996;275:423-4
83. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000;356:1949-54
84. Shibata MC, Leon H, Chatterley T, et al. Do calcium channel blockers increase the diagnosis of heart failure in patients with hypertension? Am J Cardiol 2010;106:228-35
85. Kidney Disease Outcomes Quality Initiative (K/DOQI). Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:1-290
86. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28
87. Braunwald E. Mechanism of action of calcium-channel-blocking agents. N Engl J Med 1982;307:1618-27
88. Loutzenhiser R, Epstein M. Effects of calcium antagonists on renal hemodynamics. Am J Physiol 1985;249:F619-29
89. Chellingsworth MC, Kendall MJ, Lote CJ, Thewles A. Diuresis and natriuresis after dihydropyridines: role of prostaglandin E. J Hum Hypertens 1990;4:241-5
90. Madeddu P, Oppes M, Soro A, et al. Natriuretic effect of acute nifedipine administration is not mediated by the renal kallikrein-kinin system. J Cardiovasc Pharmacol 1987;9:536-40
91. Kaplan NM. Calcium entry blockers in the treatment of hypertension: current status and future prospects. JAMA 1989;262:817-23
92. Epstein M, De Micheli AG. Natriuretic effects of calcium antagonists. In: Epstein M, editor. Calcium antagonists in clinical medicine. Hanley and Belfus; Philadelphia: 1992. p. 349-66
93. Ene MD, Williamson PJ, Roberts CJC, Waddell G. The natriuresis following oral administration of the calcium antagonists-nifedipine and nitrendipine. Br J Clin Pharmacol 1985;19:423-7
94. Kloke HJ, Branten AJ, Huysmans FT, Wetzels JF. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int 1998;53:1559-73
95. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
96. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-31
97. Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-50
98. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54:1283-9
99. Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004;65:1991-2002
100. Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998;54:889-96
101. Salomone S, Silva LM, Morel N, Godfraind T. Facilitation of the vasorelaxant action of calcium antagonists by basal nitric oxide in depolarized artery. Naunyn Schmiedebergs Arch Pharmacol 1996;354:505-12
102. Salomone S, Morel N, Godfraind T. Effects of 8-bromocyclic GMP and verapamil on depolarization-evoked Ca2+ signal and contraction in rat aorta. Br J Pharmacol 1995;114:1731-7
103. Godfraind D, Salomone S. Calcium antagonists and endothelial function: focus on nitric oxide and endothelin. Cardiovasc Drugs Ther 1996;10:439-46
104. Huang S, Simonson MS, Dunn MJ. Manidipine inhibits endothelin-1-induced [Ca2+]i signaling but potentiates endothelin's effect on c-fos and c-jun induction in vascular smooth muscle and glomerular mesangial cells. Am Heart J 1993;125:589-97
105. Muiesan G, Agabiti-Rosei E, Romanelli G, et al. Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonists. Am J Cardiol 1986;57:44D-9D
106. Agabiti-Rosei E, Muiesan ML, Romanelli G, et al. Similarities and differences in the antihypertensive effect of two calcium antagonist drugs, verapamil and nifedipine. J Am Coll Cardiol 1986;7:916-24
107. Epstein M. Calcium channel blockers and hypertension: evolving perspective-1996. Cardiovasc Drugs Ther 1997;10:883-91
108. Hossack KF, Brown BG, Stewart DK, Dodge HT. Diltiazem-induced blockade of sympathetically mediated constriction of normal and diseased coronary arteries: lack of epicardial coronary dilatory effect in humans. Circulation 1984;70:465-71
109. Papavassiliou MV, Vyssoulis GP, Karpanou EA, et al. Toutouzas PK Side effects of antihypertensive treatment with calcium channel antagonists. Am J Hypertens 2001;14:114A
110. Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens 2003;5:330-5
111. Fletcher AE, Chester PC, Hawkins CM, et al. The effects of verapamil and propranolol on quality of life in hypertension. J Hum Hypertens 1989;3:125-30
112. Castro-Chaves P, Cerqueira R, Pintalhao M, Leite-Moreira AF. New pathways of the renin-angiotensin system: the role of ACE2 in cardiovascular pathophysiology and therapy. Expert Opin Ther Targets 2010;14:485-96
113. Brunner HR, Sealey JE, Laragh JH. Renin subgroups in essential hypertension. Further analysis of their pathophysiological and epidemiological characteristics. Circ Res 1973;32:99-105
114. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955-64
115. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
116. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
117. Hannedouche T, Landais P, Goldfarb B, et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 1994;309:833-7
118. Abdulla J, Barlera S, Latini R, et al. A systematic review: effect of angiotensin converting enzyme-inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction. Eur J Heart Fail 2007;9:129-35
119. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53
120. Sanchez RA, Marco E, Gilbert HB, et al. Natriuretic effect and changes in renal haemodynamics induced by enalapril in essential hypertension. Drugs 1985;30(Suppl 1):49-58
121. Atlas SA, Case DB, Sealey JE, Laragh JH. McKinstry DN.Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension 1979;1:274-80
122. De Gennaro Colonna V, Rigamonti A, et al. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-inducedhypertensive rats. Eur J Pharmacol 2005;516:253-9
123. Imai Y, Abe K, Seino M, et al. Captopril attenuates pressor responses to norepinephrine and vasopressin through depletion of endogenous angiotensin II. Am J Cardiol 1982;49:1537-9
124. Sasaki J, Arakawa K. Effect of captopril on high-density lipoprotein subfractions in patients with mild to moderate essential hypertension. Clin Ther 1989;11:129-34
125. Paolisso G, Gambardella A, Verza M, et al. ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 1992;6:175-9
126. Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007;99:1006-12
127. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986;314:1657-64
128. Israeli ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy; a review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42
129. Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early worsening renal function after initiation of Angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 2011;4:685-91
130. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355:637-45
131. Dzau VJ. Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities and hypotheses. J Hypertens 1989;7:933-6
132. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/ American Heart Association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure) developed in collaboration with the international society for heart and lungtransplantation endorsed by the heart failure society of America. JACC 2001;38:2101-13
133. Ruilope LM. Valsartan and the kidney: review of preclinical and clinical data. Adv Ther 2001;18:57-66
134. Abassi ZA, Kelly G, Golomb E, et al. Losartan improves the natriuretic response to ANF in rats with high-output heart failure. J Pharmacol Exp Ther 1994;268:224-30
135. Fukuda M, Yamanaka T, Mizuno M, et al. Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis. J Hypertens 2008;26:583-8
136. Huang BS, Ahmad M, Tan J, Leenen FH. Sympathetic hyperactivity and cardiac dysfunction post-MI: different impact of specific CNS versus general AT1 receptor blockade. J Mol Cell Cardiol 2007;43:479-86
137. Flammer AJ, Hermann F, Wiesli P, et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens 2007;25:785-91
138. Naya M, Tsukamoto T, Morita K, et al. Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. J Am Coll Cardiol 2007;50:1144-9
139. Kintscher U, Bramlage P, Paar WD, et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a subanalysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007;6:12
140. Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005;4:6
141. Aksnes TA, Seljeflot I, Torjesen PA, et al. Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity. Metabolism 2007;56:1470-7
142. Nishimura H, Sanaka T, Tanihata Y, et al. Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. Hypertens Res 2008;31:1611-18
143. Sanchez RA, Masnatta LD, Pesiney C, et al. Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives. J Hypertens 2008;26:2393-8
144. Karagiannis A, Mikhailidis DP, Athyros VG, et al. The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? Expert Opin Ther Targets 2007;11:191-205
145. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008;148:16-29
146. Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010;11:627-36
147. Weber MA, Bakris GL, Neutel JM, et al. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens 2003;5:322-9
148. Volpe M, Ruilope LM, McInnes GT, et al. Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? J Hum Hypertens 2005;19:331-9
149. Yusuf S, Teo KK, Pogue J, et al. for the ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
150. Desai M, Stockbridge N, Temple R. Blood pressure as an example of a biomarker that functions as a surrogate. AAPS J 2006;8:E146-52
151. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension 2 study. Lancet 1999;354:1751-6
152. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-16
153. VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
154. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665
155. Fox KM; European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8
156. Ueda S. New approaches to blockade of the renin-angiotensin-aldosterone system: evidence from randomized controlled trials (RCTs) of an giotensin-converting enzyme inhibitors and angiotensin II-Receptor Blockers - Questions Remain Unsolved. J Pharmacol Sci 2010;113:292-5
157. Volpe M, Tocci G. Managing hypertension in cardiology practice according to risk profile. Int J Clin Pract 2008;62:1403-12
158. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65
159. Zanchetti A, Rosei EA, Dal Palu C, et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998;16:1667-76
160. Black HR, Elliott WJ, Grandits G, et al. CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289:2073-82
161. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004;43:4-9
162. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressare. Hypertension 2006;47:352-8
163. Maseri A. Viewpoint. Circulation 2006;113:f29-30
164. Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-5